64Cu-ATSM PET/MR imaging of hypoxia in human atherosclerosis

Xingyu Nie, PhD[1,2], **Andrew Elvington, PhD**[3], **Richard Laforest, PhD**[1], **Jie Zheng, PhD**[1], **Thomas F. Voller, MS**[1], **Mohamed A. Zayed, MD, PhD**[4], **Dana R. Abendschein, PhD**[5], **Nilantha Bandara, PhD**[1], **Jinbin Xu, PhD**[1], **Ran Li, MS**[1], **Gwendalyn J. Randolph, PhD**[3], **Robert J. Gropler, MD**[1,5], **Suzanne E. Lapi, PhD**[1,2], **Pamela K. Woodard, MD**[1,2]

[1.]Mallinckrodt Institute of Radiology, Washington University School of Medicine, St. Louis, MO

[2.]Department of Biomedical Engineering, Washington University in St. Louis, MO

[3.]Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO

[4.]Department of Surgery, Washington University School of Medicine, St. Louis, MO

[5.]Department of Medicine, Washington University School of Medicine, St. Louis, MO

Keywords

atherosclerosis; hypoxia; multimodality imaging; molecular imaging; human; Nuclear Cardiology and PET; Magnetic Resonance Imaging (MRI); Imaging

---

The macrophage-rich core of advanced human atheroma has been shown to be hypoxic, which may have implications for plaque stability.[1] Recently, we showed that the hypoxia PET imaging agent 64Cu-ATSM could be used for visualizing hypoxic cells in atherosclerosis in animal models.[2] In this study, we investigated the feasibility of 64Cu-ATSM PET/MR imaging for detecting hypoxic cells in human atherosclerotic plaque.

The cellular retention mechanism of 64Cu-ATSM is that *in vitro* Cu-ATSM undergoes bioreductive trapping under hypoxic conditions. Cu-ATSM Cu(II) is a lipophilic molecule, with high membrane permeability and low redox potential, and is reduced only in hypoxic cells. Upon the intracellular reduction, Cu-ATSM becomes trapped irreversibly and thus the radioactivity accumulates in these cells.[3]

This prospective human study was approved by the Institutional Review Board (IRB) at Washington University and all patients provided informed consent. The data that support the findings of this study are available from the corresponding author upon reasonable request. Images of sufficient diagnostic quality for further analysis were obtained in 7 neurologically asymptomatic patients (74.3 ± 6.2 years old) with carotid atherosclerosis and 50% diameter

---

Corresponding author: Pamela K. Woodard, M.D., 510 South Kingshighway Blvd #8223, St. Louis, MO 63110-1076, Phone: 314-747-3878, Fax: 314-362-2976, woodardp@mir.wustl.edu.

First author: Xingyu Nie, Ph.D., 475 Main St., 16P, New York, NY 10044, Phone: 314-983-8666, Fax: 314-362-2976

stenosis in at least one carotid artery. Dynamic PET imaging was done 0-60 min after IV injection of 740-925 MBq ^{64}Cu-ATSM with simultaneously-acquired T_1-, T_2-, PD-, and TOF-weighted MR imaging of carotid plaque. Five patients also underwent dynamic contrast-enhanced MR imaging (DCE-MRI) afterwards (20 timepoints and 12.5-sec image interval) with 0.1 mmol/kg gadolinium-based contrast agent injected at 0.5 mL/sec. The averaged 30-60 min ^{64}Cu-ATSM PET acquisition was reconstructed with 1.04×1.04×2.03 mm^3 resolution. Volumes-of-interests were drawn on the carotid plaques on MR images to determine the maximum standard uptake values (SUV_{max}). As a reference, the activity of the background (SUV_{bkg}) was calculated as the mean SUV of the blood pool within adjacent internal jugular veins. The target-to-background SUV ratios (TBR_{max}) defined as SUV_{max} corrected for SUV_{bkg} were calculated.

Among these 7 patients there were 8 carotid arteries with stenosis of 50% diameter (one patient with bilateral carotid stenoses). Of these 8 arteries, 3 left arteries displayed ^{64}Cu-ATSM focal uptake ($TBR_{max} \gg 1.6$; Figure 1, A–J). The TBR_{max} of the 3 contralateral carotid arteries and all 5 PET-negative carotid plaques as indicated by lack of detection of focal ^{64}Cu-ATSM retention (1.48 ± 0.28 and 1.53 ± 0.17, respectively) were significantly lower ($p < 0.05$ and $p < 0.001$) than those values of the plaques with positive detection of ^{64}Cu-ATSM hot spots (2.88 ± 0.17). Volume transfer constant (K^{trans}) maps determined by describing DCE-MRI with the Patlak model was in line with literature that peak K^{trans} values (0.26 ± 0.16 min^{-1}) were identified at the highly vascularized outer rim of the plaques.[4]

Of the 7 patients imaged, 3 went to surgery and had carotid endarterectomy (CEA) specimens available. Of the 3 CEA specimens 2 were collected from PET-positive plaques and 1 was from a PET-negative plaque. Analysis of the CEA specimens from the PET-positive plaques using IHC revealed that pimonidazole (PIMO) and HIF-1α positive cells co-localized with the macrophage marker CD68, as demonstrated by the overlay from slides of adjacent sections (Figure 1, K–O), whereas no PIMO or HIF-1α uptake was identified in the specimen of the PET-negative plaque. This suggests the presence of hypoxic macrophages in these specific carotid plaques.

In summary, we confirmed the feasibility of ^{64}Cu-ATSM PET/MR imaging for identifying hypoxic cells within human carotid atherosclerosis. A nearly 3-fold TBR_{max} was observed in the plaques having ^{64}Cu-ATSM retention, which is close to the published results using animal models with atherosclerotic-like lesions.[2]

The uptake of ^{64}Cu-ATSM was found centrally within lipid-rich cells of the plaque on MRI that would correspond to regions of macrophage-rich necrotic core. This conclusion was further validated by IHC staining showing that the macrophages were the hypoxic cells that were the targets of the ^{64}Cu-ATSM tracer. The demonstration that ^{64}Cu-ATSM is retained in hypoxic macrophages in advanced atherosclerosis was shown previously through *ex vivo* co-localization of PIMO and CD68 IHC staining with ^{64}Cu-ATSM autoradiography in preclinical studies.[2]

Although ^{18}F-fluorodeoxyglucose (FDG) is the most widely validated PET tracer for evaluation of atherosclerotic inflammation based on the glucose metabolism of macrophages,[2] ^{64}Cu-ATSM which targets hypoxic cells has the potential to provide complementary information for detection of advanced atherosclerosis in humans. ^{18}F-FMISO has also been used to detect plaque hypoxia.[5] Compared to ^{18}F-FMISO, ^{64}Cu-ATSM has two major advantages: higher cellular uptake and faster washout from normoxic tissue, resulting in earlier imaging after tracer injection and higher TBR_{max} (0-60 vs 120-180 min and 2.9 vs ~1.1).[5]

Although the results are preliminary, utilizing ^{64}Cu-ATSM PET imaging for identification of hypoxic cells, in association with MRI may be useful as a method of stratifying asymptomatic patients, determining which patients have plaques that may rupture and benefit from the surgical intervention of CEA, and which patients may be treated more conservatively by optimal medical therapy.

ACKNOWLEDGEMENTS

REFERENCES

1. Sluimer JC, Gasc JM, van Wanroij JL, Kisters N, Groeneweg M, Sollewijn Gelpke MD, Cleutjens JP, van den Akker LH, Corvol P, Wouters BG, et al. Hypoxia, hypoxia-inducible transcription factor, and macrophages in human atherosclerotic plaques are correlated with intraplaque angiogenesis. J Am Coll Cardiol. 2008;51:1258–65. [PubMed: 18371555]

2. Nie X, Laforest R, Elvington A, Randolph GJ, Zheng J, Voller T, Abendschein DR, Lapi SE and Woodard PK. PET/MRI of Hypoxic Atherosclerosis Using 64Cu-ATSM in a Rabbit Model. J Nucl Med. 2016;57:2006–2011. [PubMed: 27390157]

3. Fujibayashi Y, Taniuchi H, Yonekura Y, Ohtani H, Konishi J and Yokoyama A. Copper-62-ATSM: a new hypoxia imaging agent with high membrane permeability and low redox potential. J Nucl Med. 1997;38:1155–60. [PubMed: 9225812]

4. Gaens ME, Backes WH, Rozel S, Lipperts M, Sanders SN, Jaspers K, Cleutjens JP, Sluimer JC, Heeneman S, Daemen MJ, et al. Dynamic contrast-enhanced MR imaging of carotid atherosclerotic plaque: model selection, reproducibility, and validation. Radiology. 2013;266:271–9. [PubMed: 23151823]

5. Joshi FR, Manavaki R, Fryer TD, Figg NL, Sluimer JC, Aigbirhio FI, Davenport AP, Kirkpatrick PJ, Warburton EA and Rudd JH. Vascular Imaging With (18)F-Fluorodeoxyglucose Positron Emission Tomography Is Influenced by Hypoxia. J Am Coll Cardiol. 2017;69:1873–1874. [PubMed: 28385317]

FIGURE 1. Imaging of hypoxic cells in carotid atherosclerosis.
Focal ^{64}Cu-ATSM uptake was detected in the plaque (red arrow) of the left carotid artery of a representative 69-year-old male patient as displayed in (A) ^{64}Cu-ATSM PET/T_1-weighted MR fused image and (B) ^{64}Cu-ATSM PET only image. ^{64}Cu-ATSM retention was also identified in the adjacent salivary glands, and a small amount of uptake is seen in muscle. (C) and (D) are the zoomed-in view of (A) and (B) with the region of interest (ROI) placed on the carotid artery (blue box). Plaque components of intraplaque hemorrhage and lipid-rich necrotic core (LRNC) are outlined in the corresponding (E) T_1-weighted MRI, (F) T_2-

weighted MRI, (G) PD-weighted MRI, (H) TOF MRI. (I) Segmented T_1-weighted MR image shows that there was one large region of hemorrhage & LRNC core comprising 25.6% of the entire plaque area. (J) Parametric map of K^{trans} values color coded from 0 to 0.4 min^{-1} and overlaid on anatomic MR image suggest that the highly vascularized adventitia at the outer rim has the highest K^{trans} values. The IHC staining of (L) PIMO for hypoxic cells, (M) CD68 for macrophages, (N) HIF-1α for hypoxia-inducible factor-1α and (O) DAPI (4′,6-diamidino-2-phenylindole) for nuclei on adjacent slices of CEA specimen slices from this patient were co-localized as shown in orange areas (red arrow) of (K) the overlaid image. Internal elastic lamina is denoted by the yellow arrow. Asterisk and star refer to the extracellular space and carotid artery lumen, respectively.